Merck withdrew Vioxx due to increased stroke and heart attack risks, prompting global concern.
The European Medicines Agency will review similar drugs.
Celebrex and Bextra, like Vioxx, may pose risks.
Lawsuits against Merck are mounting, alleging withheld information.
Merck's earnings have suffered, impacting its market standing.
The recall has sparked legal battles and public scrutiny.
Concerns over COX-2 inhibitors persist, with potential cardiovascular risks.
Legal experts predict a surge in lawsuits against Merck.
The Vioxx recall has far-reaching implications for the pharmaceutical industry.
Ongoing investigations highlight the need for transparency and patient safety
